Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2012 Jul 23;11(10):2212–2221. doi: 10.1158/1535-7163.MCT-12-0180

Figure 4.

Figure 4

Inhibitors of the IKKβ/mTOR/VEGF pathway block obesity-mediated tumorigenesis. HFD-induced obesity mice and control (lean) mice with mammary tumors were prepared as described in Fig. 1 and then treated with or without aspirin (A), rapamycin (B), or bevacizumab (C). Tumor-bearing mice were administered aspirin at 120 mg/kg/d by subcutaneous injection; rapamycin at 5 mg/kg twice per week by intraperitoneal injection; and bevacizumab at 10 mg/kg once per week by intravenous injection (10 mice/treatment group). Tumor volume was measured after 2 weeks of drug treatment (left). Treatment with these drugs significantly reduced tumor volume in the HFD group but not in the normal chow diet (control/lean) group. Representative images of immunofluorescence staining of tumor tissues stained with indicated antibodies (middle). The relative fluorescence intensity from the images is shown on the right. The data represent the mean ± SD (10 mice per group). ND, normal chow diet. *, P < 0.05.